Treatment of CT26 tumor-bearing mice with combination of oxaliplatin with trifluridine/tipiracil (FTD/TPI), a new antimetabolite agent, induced TAM depletion and promoted CD8+ T-cell infiltration in tumors (147). The gene discussed is CD8A; the disease is neoplasm.